Healthcare provider profile · identity verified

Mina B Bhatt, MD

Internal Medicine · SEBRING, FL · NPI 1881695096

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	369	104
Levothyroxine Sodium	Levothyroxine Sodium	335	88
Losartan Potassium	Losartan Potassium	250	82
Atorvastatin Calcium	Atorvastatin Calcium	189	60
Rosuvastatin Calcium	Rosuvastatin Calcium	189	61
Simvastatin	Simvastatin	178	54
Metoprolol Succinate	Metoprolol Succinate	160	52
Lisinopril	Lisinopril	150	50
Metoprolol Tartrate	Metoprolol Tartrate	142	44
Famotidine	Famotidine	119	34
Furosemide	Furosemide	119	38
Potassium Chloride	Potassium Chloride	115	40
Omeprazole	Omeprazole	96	36
Metformin Hcl	Metformin Hcl	95	31
Clopidogrel	Clopidogrel Bisulfate	90	22
Hydrochlorothiazide	Hydrochlorothiazide	82	31
Pravastatin Sodium	Pravastatin Sodium	75	25
Gabapentin	Gabapentin	72	23
Alendronate Sodium	Alendronate Sodium	62	22
Glimepiride	Glimepiride	62	20
Hydralazine Hcl	Hydralazine Hcl	61	18
Tamsulosin Hcl	Tamsulosin Hcl	61	15
Fluticasone Propionate	Fluticasone Propionate	60	27
Pantoprazole Sodium	Pantoprazole Sodium	58	17
Eliquis	Apixaban	56	14
Montelukast Sodium	Montelukast Sodium	56	16
Carvedilol	Carvedilol	55	17
Allopurinol	Allopurinol	53	16
Azithromycin	Azithromycin	48	43
Jardiance	Empagliflozin	48	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	45	13
Ciprofloxacin Hcl	Ciprofloxacin Hcl	44	34
Gemfibrozil	Gemfibrozil	41	12
Atenolol	Atenolol	39	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	38	12
Cefuroxime	Cefuroxime Axetil	37	30
Synthroid	Levothyroxine Sodium	37	suppressed
Alprazolam	Alprazolam	36	11
Escitalopram Oxalate	Escitalopram Oxalate	35	14
Ezetimibe	Ezetimibe	33	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	31	12
Citalopram Hbr	Citalopram Hydrobromide	31	suppressed
Memantine Hcl	Memantine Hcl	30	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	28	suppressed
Ventolin Hfa	Albuterol Sulfate	28	12
Metformin Hcl Er	Metformin Hcl	27	suppressed
Ropinirole Hcl	Ropinirole Hcl	27	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Sertraline Hcl	Sertraline Hcl	26	13
Methylprednisolone	Methylprednisolone	25	22
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Glipizide	Glipizide	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Cephalexin	Cephalexin	19	16
Lovastatin	Lovastatin	18	suppressed
Ozempic	Semaglutide	18	suppressed
Azelastine Hcl	Azelastine Hcl	17	suppressed
Entresto	Sacubitril/Valsartan	17	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Ramipril	Ramipril	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Symbicort	Budesonide/Formoterol Fumarate	16	suppressed
Glipizide Er	Glipizide	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Bumetanide	Bumetanide	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	11
Buspirone Hcl	Buspirone Hcl	13	suppressed
Calcitriol	Calcitriol	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Duloxetine Hcl	Duloxetine Hcl	13	suppressed
Finasteride	Finasteride	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Primidone	Primidone	13	suppressed
Epinephrine	Epinephrine	12	suppressed
Ibandronate Sodium	Ibandronate Sodium	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error